[go: up one dir, main page]

WO2007060491A3 - Pharmaceutical compositions comprising a sodium channel blocker in combination with a mao-b- inhibitor - Google Patents

Pharmaceutical compositions comprising a sodium channel blocker in combination with a mao-b- inhibitor Download PDF

Info

Publication number
WO2007060491A3
WO2007060491A3 PCT/HU2006/000102 HU2006000102W WO2007060491A3 WO 2007060491 A3 WO2007060491 A3 WO 2007060491A3 HU 2006000102 W HU2006000102 W HU 2006000102W WO 2007060491 A3 WO2007060491 A3 WO 2007060491A3
Authority
WO
WIPO (PCT)
Prior art keywords
sodium channel
mao
inhibitor
combination
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2006/000102
Other languages
French (fr)
Other versions
WO2007060491A2 (en
Inventor
Pal Kocsis
Istvan Tarnawa
Marta Than
Karoly Tihanyi
Gyoergy Nemeth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Publication of WO2007060491A2 publication Critical patent/WO2007060491A2/en
Publication of WO2007060491A3 publication Critical patent/WO2007060491A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to novel pharmaceutical combinations with improved sodium channel blocking effect. Further, the invention relates to the use of said pharmaceutical combinations in neurodegenerative disorders, chronic pain, in disturbances of the motor system, in epilepsy, as well as in other therapeutic fields where the use of sodium channel blockers is acceptable.
PCT/HU2006/000102 2005-11-23 2006-11-23 Pharmaceutical compositions comprising a sodium channel blocker in combination with a mao-b- inhibitor Ceased WO2007060491A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0501084 2005-11-23
HU0501084A HUP0501084A2 (en) 2005-11-23 2005-11-23 New pharmaceutical compositions of high effectivity

Publications (2)

Publication Number Publication Date
WO2007060491A2 WO2007060491A2 (en) 2007-05-31
WO2007060491A3 true WO2007060491A3 (en) 2008-01-03

Family

ID=89986416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2006/000102 Ceased WO2007060491A2 (en) 2005-11-23 2006-11-23 Pharmaceutical compositions comprising a sodium channel blocker in combination with a mao-b- inhibitor

Country Status (2)

Country Link
HU (1) HUP0501084A2 (en)
WO (1) WO2007060491A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032273A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
WO2014028868A1 (en) * 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045515A2 (en) * 2002-11-15 2004-06-03 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045515A2 (en) * 2002-11-15 2004-06-03 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WAIBEL STEFAN ET AL: "Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model", JOURNAL OF NEUROLOGY, vol. 251, no. 9, September 2004 (2004-09-01), pages 1080 - 1084, XP002445339, ISSN: 0340-5354 *

Also Published As

Publication number Publication date
WO2007060491A2 (en) 2007-05-31
HUP0501084A2 (en) 2008-05-28
HU0501084D0 (en) 2006-01-30

Similar Documents

Publication Publication Date Title
EP4164694A4 (en) Arrdc1-mediated microvesicle-based delivery to the nervous system
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
WO2009043889A3 (en) Oxadiazole derivatives
WO2008139263A3 (en) Methods for slowing the progression of multiple sclerosis
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007149865A3 (en) Methods and compositions related to inhibition of ceramide synthesis
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008070268A3 (en) Pharmaceutical compositions
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
WO2009007532A3 (en) Use of a haemoglobin for the preparation of dressings and resulting dressings
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
TW200635598A (en) Oral suspension comprising meloxicam
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2008090209A3 (en) Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2007022269A3 (en) Compounds and compositions as tpo mimetics
WO2011055383A3 (en) Intranasal delivery to improve the performance of children suffering from dyslexia
WO2007075923A3 (en) Treatment of synucleinopathies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06808811

Country of ref document: EP

Kind code of ref document: A2